Fluoroquinolones: Structure and target sites

被引:80
作者
Higgins, PG
Fluit, AC
Schmitz, FJ
机构
[1] Univ Klinikum Dusseldorf, Inst Med Microbiol & Virol, D-40225 Dusseldorf, Germany
[2] Univ Utrecht, Med Ctr, Eijkman Winkler Inst Med Microbiol Infect Dis & I, NL-3508 TC Utrecht, Netherlands
关键词
fluoroquinolone; quinolone; gyrase; topoisomerase; mutation; GyrA; ParC;
D O I
10.2174/1389450033346920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The quinolones are a potent group of drugs that target the essential bacterial enzymes DNA gyrase and topoisomerase IV. DNA gyrase is the primary target of Grain negative organisms however, it is topoisomerase IV that is the primary target of Gram positive organisms. Within these enzymes is a highly conserved region centered round the active site where resistance mutations occur. These mutations are almost always identical, irrespective of organism. In spite of the homology of this region, amino acid sequence analysis shows that there are defined differences between the Gram groups, particularly in topoisomerase IV, and it is speculated that herein lies the origin of target preference. Since the first quinolone nalidixic acid was developed, the quinolones have undergone structural modifications. in particular the addition of a fluorine at position 6, to produce the fluoroquinolones. This has seen their potency and pharmakokinetic profile greatly increase. hi vitro selection of resistance mutations has allowed the observation of how resistance is acquired and some of the modifications in newer fluoroquinolones have resulted in tire shift of primary target From topoisomerase IV to gyrase with Grain Positives. Curiously, purified topoisomerase IV is still more sensitive even if gyrase is the primary target. Gyrase remains the primary target for Grain negatives.
引用
收藏
页码:181 / 190
页数:10
相关论文
共 79 条
[1]   Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV [J].
Akasaka, T ;
Onodera, Y ;
Tanaka, M ;
Sato, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :530-536
[2]   Engineering the specificity of antibacterial fluoroquinolones:: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase [J].
Alovero, FL ;
Pan, XS ;
Morris, JE ;
Manzo, RH ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :320-325
[3]  
Berger EG, 1998, TRENDS CELL BIOL, V8, P1
[4]   Structure and mechanism of DNA topoisomerase II [J].
Berger, JM ;
Gamblin, SJ ;
Harrison, SC ;
Wang, JC .
NATURE, 1996, 379 (6562) :225-232
[5]   Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases [J].
Blanche, F ;
Cameron, B ;
Bernard, FX ;
Maton, L ;
Manse, B ;
Ferrero, L ;
Ratet, N ;
Lecoq, C ;
Goniot, A ;
Bisch, D ;
Crouzet, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2714-2720
[6]   Crystal structure of the breakage-reunion domain of DNA gyrase [J].
Cabral, JHM ;
Jackson, AP ;
Smith, CV ;
Shikotra, N ;
Maxwell, A ;
Liddington, RC .
NATURE, 1997, 388 (6645) :903-906
[7]   DNA topoisomerases: Structure, function, and mechanism [J].
Champoux, JJ .
ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 :369-413
[8]   DNA gyrase and topoisomerase IV on the bacterial chromosome: Quinolone-induced DNA cleavage [J].
Chen, CR ;
Malik, M ;
Snyder, M ;
Drlica, K .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 258 (04) :627-637
[9]   TRANSCRIPTION REGULATES OXOLINIC ACID-INDUCED DNA GYRASE CLEAVAGE AT SPECIFIC SITES ON THE ESCHERICHIA-COLI CHROMOSOME [J].
CONDEMINE, G ;
SMITH, CL .
NUCLEIC ACIDS RESEARCH, 1990, 18 (24) :7389-7396
[10]   DNA cleavage is not required for the binding of quinolone drugs to the DNA Gyrase - DNA complex [J].
Critchlow, SE ;
Maxwell, A .
BIOCHEMISTRY, 1996, 35 (23) :7387-7393